Estamos realizando la búsqueda. Por favor, espere...
1551
37
173
26083
4132
2532
334
Abstract: OBJECTIVE: Paraoxonase 1 (PON-1) is a high-density lipoprotein (HDL)-associated antioxidant enzyme that plays an important role in HDL-mediated cardioprotection. Although genetic polymorphisms are known to modulate PON-1 activity, its involvement in cardiovascular disease (CVD) in rheumatoid arthritis (RA) is controversial, suggesting that other factors may modulate its function. Since anti-HDL antibodies have been found to be related to an impaired lipid profile and occurrence of CVD in RA, this study was undertaken to examine the associations between PON-1 activity, anti-HDL antibodies, and CVD according to PON1 genetic variants in patients with RA. METHODS: Serum PON-1 activity, using paraoxon as substrate, and IgG anti-HDL antibodies were quantified in 212 RA patients and 110 healthy controls. The PON1 rs662 genotype (Q>R) was determined with TaqMan probes. An additional group of 13 biologics-naive patients with RA was prospectively followed up for 3 months. RESULTS: PON-1 activity was decreased in RA patients compared to healthy controls (P?=?0.005), and an effect of the rs662 genotype was noted in both groups, with Q/Q homozygotes exhibiting the lowest PON-1 activity. The distribution of rs662 genotypes did not differ between RA patients and healthy controls (P?=?0.215). In patients carrying the Q/Q genotype, anti-HDL antibodies were associated with impaired PON-1 activity (P?= 0.010), and levels of anti-HDL antibodies were associated with decreased HDL levels (r?=?-0.680, P < 0.001) and higher prevalence of cardiovascular events, as determined in univariate and multivariate models. Furthermore, change in anti-HDL antibody levels upon tumor necrosis factor blockade was an independent predictor of improved PON-1 activity (??=?-0.369, 95% confidence interval -0.669, -0.069; P?=?0.024). CONCLUSION: PON-1 activity is impaired in RA in association with the rs662 genotype and anti-HDL antibodies, the latter being recognized as a pivotal player in the link between rs662 and CVD in patients with RA.
Fuente: Arthritis & rheumatology Vol. 68, No. 6, June 2016, pp 1367?1376
Editorial: John Wiley and Sons Ltd
Año de publicación: 2016
Nº de páginas: 10
Tipo de publicación: Artículo de Revista
DOI: 10.1002/art.39609
ISSN: 2326-5205,2326-5191
Leer publicación
RODRÍGUEZ CARRIO, JAVIER
LÓPEZ MEJÍAS, RAQUEL
ALPERI LÓPEZ, MERCEDES
LÓPEZ, PATRICIA
BALLINA GARCÍA, FRANCISCO J.
MIGUEL ANGEL GONZALEZ-GAY MANTECON
SUÁREZ, ANA
Volver